Retatrutide

What retatrutide is and how it works

Retatrutide, developed under the code LY3437943, is a single synthetic peptide with agonist activity at three receptors: GIP, GLP-1 and glucagon. Like its predecessors it carries a fatty acid chain that binds albumin, stretching the half-life to roughly six days. Two of those receptors are familiar from semaglutide and tirzepatide. The third is what the compound is about.

Adding a glucagon receptor agonist to a metabolic drug looks like a mistake on first reading. Glucagon is the hormone of the fasting state: it tells the liver to release glucose, and injecting it raises blood sugar. The counter-argument is that glucagon does more than mobilise glucose: it increases resting energy expenditure and drives fatty acid oxidation in the liver, which is why glucagon receptor agonism is studied as a way to reduce hepatic fat. The GLP-1 component suppresses glucagon-driven glucose release and keeps insulin responsive, so the arms are meant to cancel each other where they conflict and add where they do not.

The idea is older than the molecule. Oxyntomodulin, a peptide the gut releases naturally after a meal, activates both the GLP-1 and the glucagon receptor, reducing food intake while raising energy expenditure. Retatrutide reproduces that combination in a long-acting synthetic peptide and adds GIP activity on top. The three arms are tuned to different strengths rather than balanced, and the glucagon arm is deliberately the modest one, because too much of it would undo the glucose control the other two provide.

What the research shows for retatrutide

The evidence base is one randomised phase 2 trial plus a running phase 3 programme, a far smaller foundation than either authorised incretin has. That trial, published in 2023, tested 1, 4, 8 and 12 mg weekly against placebo in adults with obesity. Mean weight change was −17.5% at 24 weeks on the 12 mg dose, and −24.2% at 48 weeks against −2.1% on placebo. Those are the largest weight reductions published for a peptide of this class.

What a phase 2 trial can and cannot show

Phase 2 exists to find a dose and to look for signals, not to prove a benefit. The trial was smaller than SURMOUNT-1 or STEP 1, ran for less time, and measured weight rather than illness or survival. The weight curve had not flattened by week 48, so the 48-week figure may understate what a longer trial would show, and equally the final number is not yet known. There is no cardiovascular outcome trial, no direct comparison against tirzepatide or semaglutide, and no long-term safety record. The phase 3 TRIUMPH programme is designed to supply some of this; until it reports, every statement about retatrutide rests on one dose-finding study.

Mechanistic work points the same way: glucagon receptor agonism increases energy expenditure and hepatic fat oxidation in animal and human physiology studies, and trials in fatty liver disease form part of the development programme. What nobody has established is how much of the weight effect comes from the glucagon arm rather than from the GIP and GLP-1 arms it shares with tirzepatide, because no published trial isolates the three components in people.

Doses used in published research

The bottom row is the important one. Semaglutide and tirzepatide have licensed schedules because a regulator assessed them; retatrutide has none, anywhere. What exists is one published trial design, in which participants were escalated slowly to their assigned dose under medical supervision, because the gastrointestinal effects scale with both dose and the speed of the increase.

These figures describe a clinical trial protocol, recorded for reference and not as instructions. No validated human dose exists for a compound that has not finished development.

Safety and side effects of retatrutide

The safety picture comes from a few hundred trial participants over a matter of months, not from years of pharmacovigilance. Read it as preliminary.

• Gastrointestinal effects. Nausea, vomiting, diarrhoea and constipation were the most common adverse events, clearly dose related and most frequent during escalation.
• Heart rate. An increase in heart rate was recorded, which is the finding that most distinguishes this compound from the dual and single agonists. Glucagon receptor activity is the suspected cause. Whether it matters over years is unknown.
• Glucose. The glucagon arm did not spoil glycaemic control, but the balance between the arms is dose dependent and was tested only within the range studied.
• Unknowns. Rare events, effects on the liver, pancreas and thyroid over years, and outcomes in older or frailer people cannot be assessed from phase 2 at all.

Regulatory status of retatrutide in Europe

Retatrutide is not authorised as a medicine in the European Union, nor anywhere else. There is no dossier assessed by the European Medicines Agency, no brand name and no pharmacy supply. It is an investigational compound in phase 3, and the only lawful human exposure to it is inside an approved clinical trial.

That places it in a different legal position from semaglutide or tirzepatide. Those two exist both as authorised medicines and as research material; retatrutide exists only as research material, and any vial on sale today is an unapproved substance for laboratory use. Under EU law a medicinal product requires a marketing authorisation before it can be placed on the market, and rules on possession and personal import vary between member states. Retatrutide is not currently named on the WADA Prohibited List, which is reissued each year.

Sourcing retatrutide and checking quality

King Peptides lists it as GLP-3 RT (Retatrutide) 10 mg. The GLP-3 part is a supplier trade name rather than a scientific one: there is no hormone called GLP-3. What matters on the label is the chemical name and the lot number.

Because no pharmaceutical version exists to compare against, analytical evidence carries more weight here than anywhere else in this group. Ask for the lot-specific certificate of analysis: HPLC purity of 99% or better, and a mass spectrometry result at 4731.3 Da, the figure in the molecular panel beside this article. Retatrutide and tirzepatide differ by fewer than 100 Da, so a low-resolution mass trace will not tell them apart, and a certificate without a matching lot number says nothing about the vial in your hand. Our guide to reading a certificate of analysis goes through both checks, and the storage and reconstitution guide covers lyophilised powder at −20 °C. Dispatch is from the Netherlands: usually 1–2 business days domestically and 3–5 business days elsewhere in the EU, with no customs inside the union, while non-EU destinations such as the United Kingdom, Switzerland or Norway can face import rules and duties. Packaging is neutral and tracked, and checkout requires confirmation of research use and a minimum age of 18.

Frequently asked questions about retatrutide

Is retatrutide approved anywhere? No. It is in phase 3 under the TRIUMPH programme and holds no marketing authorisation in the EU, the United Kingdom, the United States or elsewhere.

Why add a glucagon receptor agonist at all? For energy expenditure and liver fat. Glucagon raises the metabolic rate and drives fat oxidation in the liver; the GLP-1 arm offsets its effect on blood glucose.

Is it better than tirzepatide? The phase 2 numbers are larger, but no trial has compared the two directly and the trials differ in size, length and population. The tirzepatide profile and our three-way comparison explain why cross-trial arithmetic is unreliable.

What should be made of the heart rate finding? That it is real, expected from glucagon receptor activity, small on average, and of unknown long-term significance. Phase 3 is meant to answer it.